

	Codice	ISTITUZIONE	Titolo	Budget	Nota budget StS	Punteggio finale	Progresso GRANT	Data Nascita PI	IDONEITA'
1	TRS-2019-00002022	Fondazione M. Tettamanti Menotti De Marchi ONLUS - Monza	Measurable residual disease driven strategy for one or two infusions of autologous or allogeneic non-viral, transposon-manipulated CARCIK-CD19 cells. A Phase II study in pediatric and adult patients with relapsed/refractory B cell precursor ALL (BCP-ALL).	1.499.170,69 €	da rimodulare	6	SI	08/09/1954	IDONEO, AMMESSO AL FINANZIAMENTO
2	TRS-2019-00002062	AUSL/IRCCS di Reggio Emilia	Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in Liquid Biopsy to compare in first-line therapy FOLFIRI plus CetuximAb or BevacizumAb (LIBImAb Study)	1.362.801,00 €	adeguato	6,5	NO	12/04/1959	IDONEO, AMMESSO AL FINANZIAMENTO
3	TRS-2019-00002023	Policlinico Umberto I - Università Sapienza - Roma	A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)-HYDROXYSSc	625.800,00 €	adeguato	7	NO	07/09/1959	IDONEO, AMMESSO AL FINANZIAMENTO
4	TRS-2019-00002013	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano	A phase III, randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in children with active Juvenile Idiopathic Arthritis. (CEST-JIA)	1.314.921,77 €	adeguato	7,5	NO	17/02/1975	IDONEO, AMMESSO AL FINANZIAMENTO
5	TRS-2019-00002051	Società Italiana di Diabetologia Roma	Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial. (Gliflozin in elderly Diabetic patients: A pragmatic intraclass Evaluation trial: GOLDEN AGE)	1.500.000,00 €	da rimodulare	7,5	NO	21/03/1955	IDONEO, AMMESSO AL FINANZIAMENTO
6	TRS-2019-00002113	Fondazione Policlinico Universitario "A.Gemelli" IRCCS - Roma	A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals with Fragile X Syndrome.	412.213,00 €	adeguato	8	NO	25/08/1967	IDONEO, NON AMMESSO AL FINANZIAMENTO
7	TRS-2019-00001921	IRCCS Ospedale San Raffaele - Milano	Efficacy and Safety Trial of Liraglutide, in Paediatric and Adult Patients with Wolfram Syndrome	712.900,00 €	adeguato	9	NO	16/08/1968	IDONEO, NON AMMESSO AL FINANZIAMENTO
8	TRS-2019-00002118	Azienda Ospedaliero-Universitaria Ospedali Riuniti - Ancona	A proof-of-concept study of umbilical cord mesenchymal stromal cells (UC-MSCs) infusion for systemic sclerosis associated interstitial lung disease (SSc-ILD)	340.000,00 €	adeguato	9,5	SI	27/01/1950	IDONEO, NON AMMESSO AL FINANZIAMENTO
9	TRS-2019-00002065	Azienda Ospedaliero Universitaria A. Meyer - Firenze	Randomized controlled trial to evaluate the efficacy and safety of the combined therapy, biosimilar Adalimumab plus methotrexate as first line therapy, compared with the standard sequential therapy, methotrexate and thereafter methotrexate plus Adalimumab, in steroid refractory and/or chronic uveitis of Juvenile Idiopathic Arthritis children	1.364.082,20 €	da rimodulare	10,5	NO	11/06/1972	IDONEO, NON AMMESSO AL FINANZIAMENTO
10	TRS-2019-00002002	Università di Padova - Padova	Tackling Primary Aldosteronism: new Strategies with old drugs (TAPAS)	318.500,00 €	adeguato	10,5	NO	27/06/1954	IDONEO, NON AMMESSO AL FINANZIAMENTO
11	TRS-2019-00002089	Ospedale Pediatrico Bambino - Roma	A Phase II study to assess safety and efficacy of Alisporivir (Debio 025) in patients with Collagen VI-related myopathies	998.166,00 €	non adeguato	10,5	NO	08/06/1950	IDONEO, NON AMMESSO AL FINANZIAMENTO

	Codice	ISTITUZIONE	Titolo	Budget	Nota budget StS	Punteggio finale	Pregresso GRANT	Data Nascita PI	IDONEITA'
12	TRS-2019-00002054	Università di Firenze	Randomized Controlled Trial to evaluate the efficacy of Rituximab biosimilar in the treatment of Systemic sclerosis related interstitial lung disease.	1.464.297,78 €	da rimodulare	11	NO	05/02/1956	IDONEO, NON AMMESSO AL FINANZIAMENTO
13	TRS-2019-00002021	Fondazione Policlinico Universitario - Roma	Non invasive, Point-of-care diaphragm and lung ultrasound to predict diaphragm function, atelectasis and respiratory infections in SMA children treated with nusinersen	260.700,00 €	da rimodulare	11	NO	11/01/1974	IDONEO, NON AMMESSO AL FINANZIAMENTO
14	TRS-2019-00002109	IRCCS Giannina Gaslini, Università di Genova	Efficacy of FSH+testosterone and FSH+hCG after pre-treatment with FSH compared to standard testosterone therapy on testicular volume and quality of life during pubertal induction: a randomized trial in Kallmann Syndrome/Congenital Hypogonadotropic Hypogonadism patients (FaTHER study)	1.248.110,30 €	da rimodulare	11	NO	05/05/1957	IDONEO, NON AMMESSO AL FINANZIAMENTO
15	TRS-2019-00002049	Università della Campania "L. Vanvitelli" - Napoli	daPagliflozin in fAnconi bickel syndrome: a Randomized, DOuble blind, CROSSover trial: the PARADOX study	546.068,60 €	adeguato	12	NO	15/06/1981	IDONEO, NON AMMESSO AL FINANZIAMENTO
16	TRS-2019-00002034	Azienda Policlinico Vittorio Emanuele Università di Catania	Monitoring Vaso Occlusive Crisis management in children with Sickle Cell Disease in Pediatric Onco-Hematology Centers in Italy. Opioid and Non Steroid Anti Inflammatory Drugs use for pain control	200.420,00 €	adeguato	12	NO	05/01/1961	IDONEO, NON AMMESSO AL FINANZIAMENTO
17	TRS-2019-00001977	Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara	A Phase II, Randomized with Control Group, Safety and Efficacy Study of Multiple Intrathecal Doses of Mesenchymal Stem Cell in Amyotrophic Lateral Sclerosis.	1.374.700,00 €	da rimodulare	12	NO	25/05/1955	IDONEO, NON AMMESSO AL FINANZIAMENTO
18	TRS-2019-00002025	Fondazione IRCCS Policlinico San Matteo - Pavia	Title (in English): "C1-inhibitor drugs as a preventive treatment for attacks of hereditary angioedema in children and adults"Title (in Italian): "I farmaci C1 inibitori nella prevenzione degli attacchi di angioedema ereditario in popolazioni pediatriche ed adulte"	74.643,03 €	adeguato	12,5	NO	29/04/1955	IDONEO, NON AMMESSO AL FINANZIAMENTO
19	TRS-2019-00001941	IRCCS – Associazione La Nostra Famiglia "ISTITUTO SCIENTIFICO EUGENIO MEDEA" - Ponte Lambro (CO)	Friedreich Ataxia Etravirine Study Trial	286.547,54 €	adeguato	12,5	NO	28/09/1957	IDONEO, NON AMMESSO AL FINANZIAMENTO
20	TRS-2019-00001974	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milano	Autologous transplantation of gene-modified stem cell for Duchenne Muscular Dystrophy	1.488.300,00 €	da rimodulare	13	NO	05/07/1969	IDONEO, NON AMMESSO AL FINANZIAMENTO
21	TRS-2019-00002028	ASST Santi Paolo Carlo - Milano	Repurposing Mirtazapine to target the Rett syndrome: a randomized placebo-controlled Phase II multicenter study to evaluate safety and efficacy	966.462,95 €	da rimodulare	13	NO	04/10/1969	IDONEO, NON AMMESSO AL FINANZIAMENTO
22	TRS-2019-00002078	Fondazione Italiana Ricerca Malattie Autoimmuni e Reumatiche - F.I.R.M.A.R. - Palermo	Anakinra, as first-line therapy, vs steroids in adult onset Still's disease. A multicenter randomized controlled trial, with 2 parallel groups, to show that treating patients, in an early window of opportunity, may reduce the number of flares, the severity of disease and the occurrence of life-threatening complications. thus	915.430,22 €	da rimodulare	13	NO	15/08/1957	IDONEO, NON AMMESSO AL FINANZIAMENTO
23	TRS-2019-00002010	Università di Verona - Verona	Prediction of drug response in Cystic Fibrosis	486.344,81 €	adeguato	13,5	NO	21/09/1962	IDONEO, NON AMMESSO AL FINANZIAMENTO

	Codice	ISTITUZIONE	Titolo	Budget	Nota budget StS	Punteggio finale	Progresso GRANT	Data Nascita PI	IDONEITA'
24	TRS-2019-00002071	AOU Università degli Studi della Campania "Luigi Vanvitelli" - Napoli	THERAPEUTIC TARGETING OF TYR682 RESIDUE OF AMYLOID PRECURSOR PROTEIN IN EARLY-ONSET FAMILIAR ALZHEIMER'S DISEASE PATIENTS USING THE FYN TYROSINE KINASE INHIBITOR SARACATINIB.	392.350,00 €	da rimodulare	13,5	NO	20/11/1952	IDONEO, NON AMMESSO AL FINANZIAMENTO
25	TRS-2019-00002015	Università di Padova	A Phase I/II clinical trial of hematopoietic stem cell gene therapy (HSCGT) for the treatment of Infantile Neuronal Ceroid Lipofuscinosis (INCL): a proof of concept (POC) study	1.493.978,28 €	adeguato	14	NO	10/12/1973	IDONEO, NON AMMESSO AL FINANZIAMENTO
26	TRS-2019-00001861	Università Tor Vergata - Roma	Metformin in Rett syndrome: clinical efficacy and proteostasis biomarker development	496.130,00 €	da rimodulare	14	NO	09/12/1956	IDONEO, NON AMMESSO AL FINANZIAMENTO
27	TRS-2019-00001968	Consiglio Nazionale delle Ricerche - Roma	Transcriptomic profiles of responsiveness in SMA patients treated with Nusinersen.	495.525,27 €	adeguato	14,5	NO	06/11/1964	IDONEO, NON AMMESSO AL FINANZIAMENTO
28	TRS-2019-00002006	Università Sapienza - Roma	A meta-analysis on the cardiovascular effects of new-generation targeted therapy and immunotherapy in children with cancer	40.000,00 €	adeguato	14,5	SI	25/07/1974	IDONEO, NON AMMESSO AL FINANZIAMENTO
29	TRS-2019-00002026	Azienda Ospedaliero Universitaria di Modena	Ionic homeostasis in Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multi-arm and multicenter clinical trial	1.082.320,00 €	da rimodulare	15	NO	29/04/1978	IDONEO, NON AMMESSO AL FINANZIAMENTO
30	TRS-2019-00002090	Università degli Studi dell'Aquila	Pyridostigmine treatment for Gastrointestinal manifestations in Systemic Sclerosis (PYGASS): a randomised, double-blind, placebo-controlled study.	750.329,01 €	da rimodulare	16	NO	07/12/1972	IDONEO, NON AMMESSO AL FINANZIAMENTO
31	TRS-2019-00002117	Università della Campania "Luigi Vanvitelli" - Caserta	A randomized, controlled study to assess the efficacy and safety of the administration of intramuscular Neridronate in patient affected by Duchenne Muscular Dystrophy (DMD) in prolonged treatment with glucocorticoids	383.203,40 €	da rimodulare	16	NO	05/11/1957	IDONEO, NON AMMESSO AL FINANZIAMENTO
32	TRS-2019-00001966	Università Sapienza - Roma	Efficacy of a diacerein-based anti-inflammatory therapy to reduce aortic growth in patients with thoracic aortic aneurysm: a multicentric, randomized, double-blind clinical trial.	1.269.406,00 €	da rimodulare	16	NO	07/08/1956	IDONEO, NON AMMESSO AL FINANZIAMENTO
33	TRS-2019-00002080	Università Sapienza - Roma	SYSTEMATIC REVIEW OF CONTROLLED CLINICAL TRIALS ON HEMODYNAMIC EFFECTS OF ORAL PHARMACOLOGIC TREATMENTS FOR PULMONARY ARTERIAL HYPERTENSION	42.270,19 €	adeguato	16,5	NO	27/07/1973	IDONEO, NON AMMESSO AL FINANZIAMENTO
34	TRS-2019-00002039	Università "Federico II" - Napoli	Safety and efficacy of the switch from Adalimumab originator (Humira®) to Adalimumab biosimilar ABP 501(Amgevita®) for the maintenance of remission in moderate to severe paediatric Crohn's disease.	1.317.279,42 €	da rimodulare	16,5	NO	25/05/1968	IDONEO, NON AMMESSO AL FINANZIAMENTO
35	TRS-2019-00002075	Azienda Ospedaliera Universitaria "Federico II" - Napoli	Effects of the dopamine agonist cabergoline on insulin-resistance in patients with controlled acromegaly	1.442.290,00 €	da rimodulare	16,5	NO	09/01/1970	IDONEO, NON AMMESSO AL FINANZIAMENTO

	Codice	ISTITUZIONE	Titolo	Budget	Nota budget StS	Punteggio finale	Progresso GRANT	Data Nascita PI	IDONEITA'
36	TRS-2019-00002052	Università "Aldo Moro" - Bari	A randomized, phase III trial on the biological and clinical effects of acetyl-L-carnitine in ALS	1.452.926,85 €	da rimodulare	17	NO	28/06/1955	IDONEO, NON AMMESSO AL FINANZIAMENTO
37	TRS-2019-00001975	Università degli Studi - Torino	PeRsonalizEd treatment with Lithium carbonate for Unc13a DEtermined ALS (PRELUDE)	427.000,00 €	adeguato	17,5	SI	30/08/1957	IDONEO, NON AMMESSO AL FINANZIAMENTO
38	TRS-2019-00002053	Azienda Ospedaliero Universitaria A. Meyer - Firenze	Efficacy of biologic therapy in rare paediatric rheumatology diseases: building the evidence by systematic review and meta-analysis approach.	75.000,00 €	adeguato	17,5	NO	30/06/1955	IDONEO, NON AMMESSO AL FINANZIAMENTO
39	TRS-2019-00002123	ASST Grande Ospedale Metropolitano Niguarda - Milano	Controlled Comparative Study on the Effect of Therapeutic Switch From the Originator to Trastuzumab Biosimilars and Between Biosimilars in Patients With HER2 Positive Early Breast Cancer (CASSANDRA)	1.401.000,00 €	da rimodulare	18	NO	05/05/1953	IDONEO, NON AMMESSO AL FINANZIAMENTO
40	TRS-2019-00002076	Università "Federico II" - Napoli	Ranolazine for the treatment of reduced exercise tolerance in Fabry Disease: a double blind, interventional trial on fatigue and quality of life in adult male Anderson-Fabry Disease patients	993.304,50 €	da rimodulare	18	NO	13/08/1972	IDONEO, NON AMMESSO AL FINANZIAMENTO
41	TRS-2019-00002101	Ospedale Pediatrico Bambino Gesù, IRCCS - Roma	Phase I study on safety and efficacy of CD30-directed autologous CAR T cells for relapsed/refractory Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL)	1.248.800,00 €	da rimodulare	18,5	NO	27/05/1980	IDONEO, NON AMMESSO AL FINANZIAMENTO
42	TRS-2019-00002031	Università di Milano-Bicocca	Phase II one-arm, open-label, multicenter clinical trial to assess the efficacy and safety of oral NOX1/NOX4 inhibitor (GKT137831) in patients with primary sclerosing cholangitis. The NOX-PSC study	970.477,33 €	non adeguato	18,5	NO	24/01/1968	IDONEO, NON AMMESSO AL FINANZIAMENTO
43	TRS-2019-00002124	IRCCS Ospedale San Raffaele - Milano	A MULTICENTER, OPEN-LABEL, PHASE 2 TRIAL, OF TRANSDERMAL TESTOSTERONE GEL 2% FOR PUBERTAL INDUCTION AND PROGRESSION IN ADOLESCENT BOYS WITH HYPOGONADISM	1.050.345,00 €	da rimodulare	18,5	NO	26/03/1958	IDONEO, NON AMMESSO AL FINANZIAMENTO
44	TRS-2019-00002102	IRCCS Ospedale San Raffaele - Milano	Management of CAR-T toxicity in ICU setting: a MEta-aNalysis	73.700,00 €	da rimodulare	18,5	NO	21/03/1981	IDONEO, NON AMMESSO AL FINANZIAMENTO
45	TRS-2019-00001972	ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, I.R.S.T., IRCCS - Meldola (FC)	Multicentric phase III randomized non inferiority study to compare efficacy and safety of DENosumab 120 mg, every 12 weeks vs every 4 weeks in BrEaST cancer patients with bone metastases.	649.700,00 €	adeguato	19	NO	01/09/1968	IDONEO, NON AMMESSO AL FINANZIAMENTO
46	TRS-2019-00002079	IRCCS MultiMedica - Milano	A randomized prospective double-blind arm placebo controlled study on low dose azithromycin add on standard therapy in IPF- a phase 2b study	1.087.603,00 €	da rimodulare	19	NO	29/07/1960	IDONEO, NON AMMESSO AL FINANZIAMENTO
47	TRS-2019-00002098	Fondazione IRCCS Istituto Neurologico Carlo Besta - Milano SSD Coordinamento	The efficacy of botulinum toxin for the treatment of neuropathic pain in Chiari Malformation type 1. A randomised, double-blind, placebo-controlled trial.	675.950,79 €	da rimodulare	19	NO	29/11/1958	IDONEO, NON AMMESSO AL FINANZIAMENTO

	Codice	ISTITUZIONE	Titolo	Budget	Nota budget StS	Punteggio finale	Progresso GRANT	Data Nascita PI	IDONEITA'
48	TRS-2019-00002038	Azienda Unità Locale Socio Sanitaria (ULSS) 3 "Serenissima"- Mestre	Effect of vortioxetine on apathy and other neuropsychiatric symptoms in frontotemporal dementia: a phase II randomized placebo-controlled trial	169.820,40 €	adeguato	19,5	NO	01/02/1983	IDONEO, NON AMMESSO AL FINANZIAMENTO
49	TRS-2019-00002027	Università di Cagliari	Efficacy of PPAR-alpha agonists (fenofibrate) as therapeutic aid for nocturnal frontal lobe epilepsy: a double-blind randomized multicentric trial.	524.212,69 €	da rimodulare	19,5	NO	18/11/1969	IDONEO, NON AMMESSO AL FINANZIAMENTO
50	TRS-2019-00002072	Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Milano	OVERMEDICATION AND INAPPROPRIATE TREATMENTS IN ALS PATIENTS: RISK OF ADVERSE DRUG INTERACTIONS AND EFFECTS ON DISEASE PROGRESSION	324.055,60 €	adeguato	19,5	NO	11/02/1981	IDONEO, NON AMMESSO AL FINANZIAMENTO
51	TRS-2019-00002064	AUSL-IRCCS - Reggio Emilia	Efficacy and Safety of Interferon γ -2b Treatment in Refractory Macular Edema Associated with Behçet and Eales Disease.	443.712,03 €	adeguato	21	NO	06/11/1964	IDONEO, NON AMMESSO AL FINANZIAMENTO
52	TRS-2019-00002061	Fondazione Policlinico Universitario "A.Gemelli" IRCCS - Roma	Primary Cytomegalovirus infection in the first and second trimester of pregnancy and therapy with Valacyclovir: prevention of vertical transmission and of fetal-neonatal injury. The VALCYPRE phase II randomised clinical trial	1.467.519,68 €	adeguato	21	NO	09/04/1961	IDONEO, NON AMMESSO AL FINANZIAMENTO
53	TRS-2019-00001924	Centro Cardiologico Monzino IRCCS - Milano	EffectS of n-acEtylcysteine on ARrhythmogeniclC Cardiomyopathy pHenotypes (SEARCH)	905.020,00 €	da rimodulare	21	NO	07/12/1972	IDONEO, NON AMMESSO AL FINANZIAMENTO
54	TRS-2019-00002120	Università di Firenze	Evaluation of the efficacy and safety profile of Originator and Biosimilar drugs in naïve or Switching adult and pediatric patients with noninfEctiouS uveitiS	251.973,23 €	adeguato	22	NO	01/05/1980	NON IDONEO
55	TRS-2019-00002050	Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Milano	Safety and efficacy of low-cost biosimilar Truxima compared to the high cost Mabthera in the treatment of primary membranous nephropathy	1.214.503,40 €	da rimodulare	22,5	SI	18/01/1962	NON IDONEO
56	TRS-2019-00002055	Università di Firenze	Efficacy, Effectiveness and Safety of biological therapy in the treatment of Behçet's Disease (BD): a network meta-analysis	73.527,44 €	adeguato	22,5	NO	01/04/1971	NON IDONEO
57	TRS-2019-00002056	Policlinico Umberto I - Roma	IDENTIFICATION OF NEW MARKERS TO PREVENT TUMORS AND CARDIOVASCULAR DISEASE IN SUBJECTS WITH MUTATIONS IN THE ATM (ATAXIA TELEANGIECTASIA, MUTATED) GENE.	463.659,65 €	adeguato	24,5	NO	16/06/1954	NON IDONEO
58	TRS-2019-00002037	AOU Policlinico Federico II - Napoli	iHOBInnovations in Hypothalamic ObesityA multicenter study to evaluate differences in efficacy of Ketogenic diet, bariatric surgery and liraglutide in hypothalamic obesity patients	497.264,29 €	adeguato	24,5	SI	04/09/1958	NON IDONEO
59	TRS-2019-00001932	Università di Firenze	A Prospective, Multicentre, Randomized, Active Control, Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated with Hypoparathyroidism by Replacement of Currently Used Calcium Supplements in Adults with Hypoparathyroidism	1.064.807,00 €	da rimodulare	26	SI	31/07/1953	NON IDONEO

	Codice	ISTITUZIONE	Titolo	Budget	Nota budget StS	Punteggio finale	Progresso GRANT	Data Nascita PI	IDONEITA'
60	TRS-2019-00002119	Azienda ospedaliero-Universitaria "Policlinico Vittorio Emanuele" - Catania	Role of Micro RNA in the diagnosis, prognosis and therapeutic approach of IPF	795.000,00 €	adeguato	26	NO	09/08/1979	NON IDONEO
61	TRS-2019-00002073	Università di Palermo	Chimeric Antigen Receptors T-cell (CAR-T cells) therapy: efficacy evaluation of pediatric tumors treatment e a meta-analysis	74.886,39 €	adeguato	26	NO	01/12/1957	NON IDONEO
62	TRS-2019-00002095	Azienda Ospedaliera di Padova – Università di Padova	Switching from Originator Infliximab to CT-P13 and SB2 followed by switching between Biosimilars (the PASwitch study): a randomized, double-blind, non-inferiority trial.	1.489.018,31 €	da rimodulare	26,5	NO	09/08/1979	NON IDONEO
63	TRS-2019-00002081	Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma	Effects of Enzyme Replacement Therapy on Myocardial Mechanics and Exercise Tolerance in Fabry Disease			> 21*			NON IDONEO
64	TRS-2019-00002082	Azienda Ospedaliera Universitaria Integrata - Verona	Measuring CFTR function in sweat glands for predicting and monitoring effects of CFTR modulators in cystic fibrosis patients.			> 21*			NON IDONEO
65	TRS-2019-00002091	Ospedale Pediatrico Bambino Gesù, IRCCS - Roma	An open-label exploratory study of theophylline in subjects with activated phosphoinositide 3 kinase (PI3K) delta syndrome (APDS) and autoimmune lymphoproliferative syndrome (ALPS).			> 21*			NON IDONEO
66	TRS-2019-00002106	Università della Campania "L. Vanvitelli" - Napoli	Could the effects of Epigenetic-sensitive modifications be reverted by current approved drugs for Pulmonary Arterial Hypertension? A systematic Review and meta-analysis (CLEOPAHTRA)			> 21*			NON IDONEO
67	TRS-2019-00002111	U.O.C. Oncologia - AORN A. Cardarelli - Napoli	Switching between TRASTuzumab originator and biosimilars in patients with early breast cancer: a 144-week randomized clinical trial			> 21*			NON IDONEO
68	TRS-2019-00002122	Università di Firenze	Safety and efficacy of switch between rituximab and ocrelizumab treatments in relapsing multiple sclerosis patients.			> 21*			NON IDONEO

*Punteggio superiore a 21 già dopo la valutazione dei primi 4 criteri